Announcement Eli Lilly has agreed with the legal body, the US government and has entered an agreement to extend its reach to its obesity treatments for self-pay patients and Medicare beneficiaries. This will prominently mitigate the monthly out-of-the-budget costs. The efforts behind this decision ...
Announcement The major IAVI’s Lassa virus (LASV) vaccine candidate findings from a first-in-human, Phase 1 clinical trial are now on the page of New England Journal of Medicine. The published data elaborates that one dose of the vaccine provokes comprehensive long-standing immune responses a...
Announcement GeneDx, a captain of improved health outcomes, shores delivering excellence via genomic insights, has hinted that it will soon reveal the research findings at a time of four major sessions at the National Society of Genetic Counsellors (NSGC) Annual Meeting 2025. The PhD, FACMG, SVP of...
Announcement Eli Lilly’s amylin agonist, eloralintide, successfully showed 20% of weight loss in its mid-stage study that marked the course for the phase 3 trial. The analyst, William Blair, claimed that eloralintide examines the amylin agonist class. The Phase 2 trial for the same involved ...
Announcement Novo Nordisk and Eli Lilly will provide their GLP-1 drugs via President Donald Trump’s direct-to-consumer marketplace for worth $350 per month. The future pills manufactured by industries like Novo’s oral Wegovy or any GLP-1 pill that received approval later will be availa...
Announcement IDT Biologika GmbH, the leading European auxiliary of SK Bioscience, has sailed on a full-scale ocean to extend its contract development and manufacturing (CDMO) business in biopharmaceuticals and vaccines. Last month and the start of November, the IDT took part in three of the compan...
Announcement The alliances have evolved and faced the challenges together to build a healthy tomorrow. The latest partnership has been introduced in the vast healthcare market. The PolyActiva, a clinical-level biopharmaceutical company standing in a well-defined position with the novel drug deliver...
Announcement The Kardigan, the leading heart health company advancing cardiovascular (CV) drug development, has acquired Prolaio, a clinical-fuelled company modernising care and research with real-world patient insights and data. Additionally, Prolaio’s FDA-approved patient monitoring softwa...
Announcement Precision Biologics, Inc. declared in vivo and in vitro efficacy of its novel tumor-specific ADC (PB-vcMMAE-5) in competition against human carcinomas reacting with truncated core 2 O-glycans. The current data for various human cancer types, précising truncated core 2 O-glycans...
Announcement OrsoBio, a leading clinical-level biopharmaceutical company working towards the development of related metabolic disorders and obesity treatments, have showcased the presentation of new preclinical and clinical data at ObesityWeek® 2025 held in Atlanta, Ga, on November 4-7. The com...
